Biovica announces two new customers and sales of 1,5 MSEK

2019-03-19 08:00

Uppsala, the 19th of March 2019. Two new customers have purchased DiviTum®-kits in order to evaluate response to treatment in breast cancer studies. The customers are pharma- and CRO-companies (Contract Research Organization) based in US and Europe.

“We are glad to see that there is a demand for DiviTum® on the research market and an interest to include it in clinical trials in order to effectively follow up cancer treatments. We’re pleased that pharma companies see the value of our product and use it in clinical trials in order to provide better treatments for the patients.”, says Anders Rylander, CEO Biovica.

Some of our Collaborations

>3200

Numbers of patients in studies

24

Publications

10

Pharma Contracts